Juan I Rojas1,2,3, Agustín Pappolla4, Liliana Patrucco5, Edgardo Cristiano5, Jimena Miguez4, Susana Liwacki6,7, Verónica Tkachuk8, María E Balbuena8, Carlos Vrech9, Norma Deri10, Jorge Correale11, Mariano Marrodan11, María C Ysrraelit11, Marcela Fiol11, Felisa Leguizamon12, Geraldine Luetic13, María L Menichini14, Pablo A Lopez15, Juan Pablo Pettinicchi15, Juan Criniti15, Alejandro Caride15, Darío Tavolini16, Carolina Mainella17, Gisela Zanga18, Marcos Burgos19, Javier Hryb20, Andrés Barboza21, Luciana Lazaro22, Ricardo Alonso23,22, Berenice Silva23, Nora Fernández Liguori22, Débora Nadur8,24, Aníbal Chercoff25, Alejandra Martinez25, Judith Steinberg25, Orlando Garcea23, Adriana Carrá25, Marina Alonso Serena26, Edgar Carnero Contentti15. 1. Centro de Esclerosis Múltiple de Buenos Aires, CABA, Argentina. rojasjuanignacio@gmail.com. 2. Centro Universitario de Esclerosis Múltiple, Hospital Ramos Mejía, Buenos Aires, Argentina. rojasjuanignacio@gmail.com. 3. Centro de Esclerosis Múltiple de Buenos Aires, (CEMBA), Billinghurst 1611, CP 1181, Buenos Aires, Argentina. rojasjuanignacio@gmail.com. 4. Servicio de Neurología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. 5. Centro de Esclerosis Múltiple de Buenos Aires, CABA, Argentina. 6. Clínica Universitaria Reina Fabiola, Cordoba, Argentina. 7. Servicio de Neurología - Hospital Córdoba, Cordoba, Argentina. 8. Sección de Neuroinmunología Y Enfermedades Desmielinizantes, Servicio de Neurología - Hospital de Clínicas José de San Martín, CABA, Argentina. 9. Departamento de Enfermedades Desmielinizantes - Sanatorio Allende, Cordoba, Argentina. 10. Centro de Investigaciones Diabaid, CABA, Argentina. 11. Departamento de Neurología - FLENI, CABA, Argentina. 12. Hospital de Agudos, Dr. Teodoro Álvarez, CABA, Argentina. 13. Instituto de Neurociencias de Rosario, Santa Fe, Argentina. 14. Sanatorio Británico, Rosario, Santa Fe, Argentina. 15. Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires, Argentina. 16. INECO Neurociencias Oroño, Rosario, Santa Fe, Argentina. 17. Hospital Español de Rosario, Santa Fe, Argentina. 18. Unidad Asistencial César Milstein, CABA, Argentina. 19. Servicio de Neurología - Hospital San Bernardo, Salta, Argentina. 20. Servicio de Neurología - Hospital Carlos G. Durand, CABA, Argentina. 21. Hospital Central de Mendoza, Mendoza, Argentina. 22. Sanatorio Güemes, CABA, Argentina. 23. Centro Universitario de Esclerosis Múltiple, Hospital Ramos Mejía, Buenos Aires, Argentina. 24. Hospital Naval, CABA, Argentina. 25. Sección de Enfermedades Desmielinizantes - Hospital Británico, CABA, Argentina. 26. Servicio de Clínica Médica, Hospital Italiano de Buenos Aires, CABA, Argentina.
Abstract
The objective was to evaluate time to reach an EDSS of 4, 6, and 7 in NMOSD and MOGAD patients included in the Argentinean MS and NMOSD registry (RelevarEM, NCT 03,375,177). METHODS: NMOSD patients diagnosed according to 2015 criteria and with MOGAD were identified. Patients with at least 3 years of follow-up and periodic clinical evaluations with EDSS outcomes were included. AQP4-antibody and MOG-antibody status was recorded, and patients were stratified as seropositive and seronegative for AQP4-antibody. EDSS of 4, 6, and 7 were defined as dependent variables. Log rank test was used to identify differences between groups. RESULTS: Registry data was provided for a total of 137 patients. Of these, seventy-five presented AQP4-ab-positive NMOSD, 45 AQP4-ab-negative NMOSD, and 11 MOGAD. AQP4-ab status was determined by cell-based assay (CBA) in 72% of NMOSD patients. MOG-ab status was tested by CBA in all cases. Mean time to EDSS of 4 was 53.6 ± 24.5 vs. 63.1 ± 32.2 vs. 44.7 ± 32 months in seropositive, seronegative NMOSD, and MOGAD, respectively (p = 0.76). Mean time to EDSS of 6 was 79.2 ± 44.3 vs. 75.7 ± 48.6 vs. 54.7 ± 50 months in seropositive, seronegative NMOSD, and MOGAD (p = 0.23), while mean time to EDSS of 7 was 86.8 ± 54 vs. 80.4 ± 51 vs. 58.5 ± 47 months in seropositive, seronegative NMOSD, and MOGAD (p = 0.39). CONCLUSION: No differences were observed between NMOSD (seropositive and seronegative) and MOGAD in survival curves.
The objective was to evaluate time to reach an EDSS of 4, 6, and 7 in NMOSD and MOGAD patients included in the Argentinean MS and NMOSD registry (RelevarEM, NCT 03,375,177). METHODS: NMOSD patients diagnosed according to 2015 criteria and with MOGAD were identified. Patients with at least 3 years of follow-up and periodic clinical evaluations with EDSS outcomes were included. AQP4-antibody and MOG-antibody status was recorded, and patients were stratified as seropositive and seronegative for AQP4-antibody. EDSS of 4, 6, and 7 were defined as dependent variables. Log rank test was used to identify differences between groups. RESULTS: Registry data was provided for a total of 137 patients. Of these, seventy-five presented AQP4-ab-positive NMOSD, 45 AQP4-ab-negative NMOSD, and 11 MOGAD. AQP4-ab status was determined by cell-based assay (CBA) in 72% of NMOSD patients. MOG-ab status was tested by CBA in all cases. Mean time to EDSS of 4 was 53.6 ± 24.5 vs. 63.1 ± 32.2 vs. 44.7 ± 32 months in seropositive, seronegative NMOSD, and MOGAD, respectively (p = 0.76). Mean time to EDSS of 6 was 79.2 ± 44.3 vs. 75.7 ± 48.6 vs. 54.7 ± 50 months in seropositive, seronegative NMOSD, and MOGAD (p = 0.23), while mean time to EDSS of 7 was 86.8 ± 54 vs. 80.4 ± 51 vs. 58.5 ± 47 months in seropositive, seronegative NMOSD, and MOGAD (p = 0.39). CONCLUSION: No differences were observed between NMOSD (seropositive and seronegative) and MOGAD in survival curves.
Authors: Edgar Carnero Contentti; Pablo A Lopez; Juan Pablo Pettinicchi; Juan Criniti; Agustín Pappolla; Jimena Miguez; Liliana Patrucco; Edgardo Carnero Contentti; Susana Liwacki; Verónica Tkachuk; María E Balbuena; Carlos Vrech; Norma Deri; Jorge Correale; Mariano Marrodan; María C Ysrraelit; Felisa Leguizamon; Geraldine Luetic; María L Menichini; Darío Tavolini; Carolina Mainella; Gisela Zanga; Marcos Burgos; Javier Hryb; Andrés Barboza; Luciana Lazaro; Ricardo Alonso; Nora Fernández Liguori; Débora Nadur; Aníbal Chercoff; Marina Alonso Serena; Alejandro Caride; Friedemann Paul; Juan I Rojas Journal: Mult Scler J Exp Transl Clin Date: 2021-08-20